Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1258-1262

  Choi, Jin Sung ^a   Kim, Kyung Hee ^a   Jeon, You Kyung ^a   Kim, Sung Hee ^a   Jang, Sang Geun ^a   Ku, Ja Lok ^a   Park, Jae Gahb ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

ADAM23 gene; Cancer cell lines; Colorectal cancer; Methylation; Methylation specific PCR (MSP)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADAM 23 PROTEIN; ADAM PROTEIN; UNCLASSIFIED DRUG; ADAM23 PROTEIN, HUMAN; DNA; PRIMER DNA;

ADAM23 GENE; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL INTERACTION; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER HYPERMETHYLATION; PROMOTER REGION; COLORECTAL TUMOR; DISEASE COURSE; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL LINE;

ADAM PROTEINS; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 60549087378     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24023     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics. CA Cancer J Clin 2008;58:71 - 96.
2. Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW, Ohrr HC, Ahn DH, Ferlay J, Parkkin DM, Oh DK, Park JG. Cancer incidence in Korea. Cancer Res Treat 2002;34:405 - 8.
3. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643 - 9.
4. Judson H, Stewart A, Leslie A, Pratt NR, Baty DU, Steele RJ, Carey FA. Relationship between point gene mutation, chromosomal abnormality, and tumor suppressor gene methylation status in colorectal adenomas. J Pathol 2006;210:344 - 50.
5. Song F, Smith JF, Kimura MT, Morrow AD, Matsuyama T, Nagase H, Held WA. Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression. Proc Natl Acad Sci USA 2005;102:3336 - 41.
6. Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 2005;19:563 - 73.
7. Adcock IM, Ford P, Barnes PJ, Ito K. Epigenetics and airways disease. Respir Res 2006;7:21.
8. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6:597 - 610.
9. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457 - 63.
10. Paz MF, Wei S, Cigudosa JC, Rodriguez-Perales S, Peinado MA, Huang TH, Esteller M. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 2003;12:2209 - 19.
11. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400 - 13.
12. Costa FF, Verbisck NV, Salim AC, Ierardi DF, Pires LC, Sasahara RM, Sogayar MC, Zanata SM, Mackay A, O'Hare M, Soares F, Simpson AJ, et al. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene 2004;23:1481 - 8.
13. Emi M, Katagiri T, Harada Y, Saito H, Inazawa J, Ito I, Kasumi F, Nakamura Y. A novel metalloprotease/disintegrin-like gene at 17q21.3 is somatically rearranged in two primary breast cancers. Nat Genet 1993;5:151 - 7.
14. Wu E, Croucher PI, McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of hematological malignancies. BBRC 1997;235:437 - 42.
15. Costa FF, Colin C, Shinjo SM, Zanata SM, Marie SK, Sogayar MC, Camargo AA. ADAM23 methylation and expression analysis in brain tumors. Neurosci Lett 2005;380:260 - 4.
16. Takada H, Imoto I, Tsuda H, Nakanishi Y, Ichikura T, Mochizuki H, Mitsufuji S, Hosoda F, Hirohashi S, Ohki M, Inazawa J. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 2005;24:8051 - 60.
17. Park HW, Kang HC, Kim IJ, Jang SG, Kim K, Yoon HJ, Jeong SY, Park JG. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer 2007;120:7 - 12.
18. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7 - 30.
19. Frigola J, Sole X, Paz MF, Moreno V, Esteller M, Capella G, Peinado MA. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet 2005;14:319 - 26.
20. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO, Park JG. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 2004;23: 6736 - 42.